March 16, 2022 7:52am

I have an “itchy finger” to activate some exits …

I do NOT always try to motivate others to SELL into WEAKNESS unless there are “crushing” reasons ahead; it’s SELL into strength percentage-wise I advise

Pre-open indications: 7 SELLs and 5 BUYs indications and 1 pimp/pump/promote

RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Just the facts … I ask questions and note the indications of what could or might happen …

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

 

Dow futures are UP +1.11% (+372 points), S&P futures are UP +1.25% (+53 points) and NASDAQ futures are UP +1.84% (+248 points)

 

Stock futures rose Wednesday as traders awaited the Fed’s latest monetary policy decision (which is always built-in), rallying on rumors that a ceasefire “could” be possible in the Russia-Ukraine war,

European stocks were trading higher as global markets await the latest monetary policy figures and economic forecasts from the U.S. Federal Reserve,

Asia-Pacific stocks were mostly higher, though markets in mainland China were mixed amid the Covid resurgence in the country.

 

Henry’omics:

Wednesday’s gains came ahead of a critical Fed meeting, which is widely expected to raise rates by a quarter point, the first hike since 2018.

Investors this week have been gearing up to receive the Fed's latest monetary policy decision this afternoon, which is likely to show the first of multiple interest rate hikes this year.

 

**** Investors should watch Ukrainian President Volodymyr Zelenskyy address Congress ****

 

Benchmarks advanced Tuesday alongside a sharp pullback in oil prices, which in recent weeks have surged on fears the war in Ukraine will cut global economic growth.

 

Economic Data docket: the retail sales report for February.

 

RegMed Investors’ (RMi) closing bell: “it’s about time for the oversold cell and gene therapy sector logjam to come back to appreciation.” … https://www.regmedinvestors.com/articles/12342

Ebb and flow –

·         March – 7 negative and 4 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 1 holiday, 1 neutral, 13 negative and 6 positive closes

Research Notes:

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ...  26 total to date (ATHX & ATHX) this week

 

Companies in my headlights – It’s your decision; I provide ideas and context:

SELL into Strength:

Agenus (AGEN) closed up +$0.04 to $2.66 and has a negative -$0.05 or -1.88% pre-open indication.

Chinook Therapeutics (KDNY) closed up +$0.33 to $12.75 with a negative -$0.75 or -5.88% pre-open indication.

bluebird bio (BLUE) closed up +$0.40 to $4.47 with a flat pre-open indication.

Fate Therapeutics (FATE) closed up +$1.64 to $31.31 after Monday’s -$3.88 to $29.67, Friday’s -$1.93, Thursday’s +$0.07 and last Wednesday’s +$2.64 with a negative -$0.10 or -0.32% pre-open indication.

uniQure NV (QURE) closed up +$0.53 to $15.07 with a negative -$0.19 or -1.27% pre-open indication.

Caribou Therapeutics (CRBU) closed up +$0.15 to $8.57 after Monday’s -$0.77 to $8.42, Friday’s -$0.33 and Thursday’s-$0.24 with a negative -$0.37 or -4.32% with a pre-open indication.

Precigen (PGEN) closed up +$0.03 to $1.94 after Monday’s -$0.15 to $1.91 with a negative -$0.09 or -4.64% pre-open indication.

 

BUY

Beam Therapeutics (BEAM) closed up +$1.51 to $55.24 after Monday’s -$7.18 to $53.73 after Friday’s -$4.81 to $60.91, Thursday’s +$0.61 and last Wednesday’s +$2.64 with a positive +$0.15 or +0.29% pre-open indication.

Intellia Therapeutics (NTLA) closed down again -$0.53 to 458.27 after Monday’s -$2.49 to $58.80, Friday’s-$4.62 to $61.29 and Thursday’s -$0.08 with a positive +$1.73 or 2.97% pre-open indication.

Sangamo Therapeutics (SGMO) closed up +40.01 to $5.24 with a positive +$0.26 or +4.96% pre-open indication.

CRISPR Therapeutics (CRSP) closed up +$1.98 to $60.04 after Monday’s -$3.36 to $58.06, Friday’s -$1.01, Thursday’s +$0.01 with a positive +$2.73 or +4.55% pre-open indication.

Ionis Pharmaceuticals (IONS) closed up +$0.02 to $32.70 with a positive +$0.12 or +0.37% pre-open indication.

 

Pimp/Pump and Promote:

Biostage (OTCQB: BSTG) closed down -$0.30 to $4.00 with 380 shares traded after Monday’ 28 shares traded after Friday’s +$0.39 to $4.30 with 1,602 shares traded, Thursday’s -$0.63 with 488 shares traded and last Wednesday’s -$0.26 with 1,225 shares traded …

  • WHO is BUYING these shares of a company with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?
  • Also, by use of the pump/promote process; is BSTG preparing to register the outstanding private placement (PP) shares for a reverse to initiate an offering …
  • BSTG is NOT going ANYWHERE without a cash infusion.

 

The BOTTOM LINE:  Sector investors need patience and fortitude, keeping many on HOLD waiting for rally attempt can signal a new uptrend.

The stock market posted strong action Tuesday, as the major stock indexes finished with big gains. But a key element of a follow-through day — higher volume than the previous day — was lacking.

Today is definitely another throw-of-the-dice game; it all depends on the Nasdaq.

Could a new rally be attempted after recent lows?

Negative news is the bane of these days of March with everything that has been written and shown on the TV.

Reiterating, “Fed policymakers meet this week (3/15-16) on St. Patrick’s Day (to drive the snakes into not, out of interest rates) … the Fed will almost certainly raise rates by a quarter point on Wednesday afternoon, and signal several more Fed rate hikes.”

I believe many of the oversold show buy signals but very likely will reverse lower.

There is no clear trend, and no reason to make any BUYS - however, the better way of saying but … short-term pops are (to me) clearly evident.

As I have stated yesterday, “bounce, baby, bounce”.

Earnings’ reporting on the horizon:

·         Cellectis SA (CLLS) Thursday, 3/22

·         Caladrius Biosciences (CLBS) Tuesday, 3/22

·         Brainstorm Cell Therapeutics (BCLI), Monday, 3/28

Investors should focus on forward-looking guidance, last year’s operating losses i.e., spending and cash positions or runways!

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider their investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.

 

WHY do I keep reporting on Biostage (BSTG): I WAS there to experience what occurred and saw the decay of transparency and more; it defines purpose that takes courage, resolve and patience to stay the course of asking the questions without response!